Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 7, 1983 - Issue 6
9
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Formation of Cross-Linked Asymmetrical Hybrid Hemoglobins by Double-Headed Aspirin

, , &
Pages 533-553 | Received 09 May 1983, Accepted 30 Aug 1983, Published online: 07 Jul 2009
 

Abstract

Double-headed aspirin [bis(3,5-dibromosalicyl) fumarate] selectively cross-links hemoglobin molecules between Lys 82β1 and Lys 82β2 and increases solubility of deoxy-Hb S (Walder et al., J. Mol. Biol., 141:195, 1980 and Kikugawa et al., J. Biol. Chem., 257: 7525, 1982). We reacted this reagent with the mixture of Hb A and Hb S and the mixture of Hb S and Hb York (β146His→Pro). Crosslinked asymmetrical hybrid hemoglobins (α2 β-β S and α2 β YS) were produced in high yields in addition to the cross-linked parent hemoglobin molecules. Results on electrophoresis, gel electrofocusing, ion exchange column chromatography, mechanical stability and oxygen binding properties showed that the cross-linked asymmetrical hybrid hemoglobins had properties intermediate between those of the cross-linked parent hemoglobins. Oxygen affinities of the cross-linked asymmetrical hybrids were not affected by the addition of 2,3-diphosphoglycerate (DPG) or inositol hexaphosphate, probably due to the presence of a fumaryl group at the DPG binding site.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.